Combined VEGFR and MAPK pathway inhibition in angiosarcoma

Combined inhibition of the VEGF and MAPK pathways with cediranib and trametinib had an additive effect in in vitro models, and a combinatorial effect in an in vivo model. Combined treatment led to smaller tumors than treatment with either agent alone. RNA-seq demonstrated distinct expression signatures between the trametinib treated tumors and those treated with both trametinib and cediranib. Mice with murine SVR xenografts were treated with vehicle, trametinib, cediranib, or the combination and RNA was isolated from whole tumor lysate